PMS-TETRABENAZINE 25 MG
TETRABENAZINE : 25 MG · DIN 02402424 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-TETRABENAZINE?
PMS-TETRABENAZINE 25 MG contains TETRABENAZINE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02402424, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 26-Feb-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-TETRABENAZINE used for?
Hyperkinetic movement disorders such as Huntington’s chorea, hemiballismus, senile chorea, tic and Gille’s de la Tourette’s syndrome and tardive dyskinesia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02402424 |
|---|---|
| Brand name | PMS-TETRABENAZINE |
| Generic / active ingredient | TETRABENAZINE : 25 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N07XX06 TETRABENAZINE |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Feb-2013 |
| Original market date | 2017-12-01 00:00:00 |
How is it administered?
Initial dose should be low and titrated slowly based on tolerance and responsiveness. Reassess periodically. Dosage requirements may be influenced by CYP2D6 metabolizer status.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly specified in provided text.
How is it supplied?
Not explicitly specified in provided text (mentions 25 mg tablets).
Contraindications
Hypersensitivity; untreated/inadequately treated depression; history of depression (unless under specialist care); MAOI use; hepatic impairment; reserpine use.
Warnings and precautions
Increased risk of depression and suicidality; Neuroleptic Malignant Syndrome (NMS); Parkinsonism; Akathisia; Sedation; QTc prolongation; Orthostatic hypotension; Dysphagia.
What can be used instead?
Other Canadian products sharing ATC code N07XX06 TETRABENAZINE. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-TETRABENAZINE | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02407590 |
| NITOMAN | 25 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02199270 |
| TETRABENAZINE TABLETS | 25 MG | TABLET | STERIMAX INC | DORMANT | DIN 02410338 |
Who else supplies TETRABENAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TETRABENAZINE appears in 15 registered pack listings across 7 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.